

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003082	Serial No. 10/620,850
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Pages 1, 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0025319	Feb. 28, 2002	Brams	424	178.1	
	A2	2003/0004097	Jan. 02, 2003	Schroit	514	7	
	A3	2003/0228625	Dec. 11, 2003	Toh <i>et al.</i>	435	7.1	
	A4	2004/0131621	Jul. 08, 2004	Thorpe <i>et al.</i>	424	159.1	
	A5	2004/0131622	Jul. 08, 2004	Thorpe <i>et al.</i>	424	159.1	
	A6	2004/0161429	Aug. 19, 2004	Thorpe <i>et al.</i>	424	178.1	
	A7	2004/0170620	Sep. 02, 2004	Thorpe <i>et al.</i>	424	130.1	
	A8	2004/0208868	Oct. 21, 2004	Thorpe <i>et al.</i>	424	144.1	
	A9	2004/0219155	Nov. 04, 2004	Thorpe <i>et al.</i>	424	178.1	
	A10	2004/0265367	Dec. 30, 2004	Thorpe <i>et al.</i>	424	450	
	A11	2005/0002941	Jan. 06, 2005	Thorpe <i>et al.</i>	424	178.1	
	A12	2005/0031620	Feb. 10, 2005	Thorpe <i>et al.</i>	424	155.1	
	A13	2005/0129696	Jun. 16, 2005	Thorpe <i>et al.</i>	424	155.1	
	A14	2005/0136059	Jun. 23, 2005	Thorpe <i>et al.</i>	424	155.1	
	A15	5,660,827	Aug. 26, 1997	Thorpe <i>et al.</i>	424	152.1	
	A16	5,677,171	Oct. 14, 1997	Hudziak <i>et al.</i>	435	7.23	
	A17	5,863,538	Jan. 26, 1999	Thorpe <i>et al.</i>	424	136.1	
	A18	6,300,308	Oct. 09, 2001	Schroit	514	8	
	A19	6,312,694	Nov. 06, 2001	Thorpe <i>et al.</i>	424	178.1	
	A20	6,333,348	Dec. 25, 2001	Vogel <i>et al.</i>	514	449	
	A21	6,406,693	Jun. 18, 2002	Thorpe <i>et al.</i>	424	130.1	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003082	Serial No. 10/620,850
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Pages 1, 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A22	6,783,760	Aug. 31, 2004	Thorpe <i>et al.</i>	424	178.1	
	A23	6,806,354	Oct. 19, 2004	Schroit	530	387.1	
	A24	6,818,213	Nov. 16, 2004	Thorpe <i>et al.</i>	424	130.1	
	A25	7,067,109	Jun. 27, 2006	Thorpe <i>et al.</i>	424	1.49	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 00/02584	Jan. 20, 2000	PCT			
	B2	WO 00/02587	Jan. 20, 2000	PCT			
	B3	WO 01/03735	Jan. 18, 2001	PCT			
	B4	WO 01/68709	Sep. 20, 2001	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Balasubramanian and Schroit, "Aminophospholipid Asymmetry: A Matter of Life and Death", <i>Annu. Rev. Physiol.</i> , 65:701-734, 2003.
	C2	Beck <i>et al.</i> , "Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth and Metastasis of Orthotopic Pancreatic Tumors in Mice," <i>Int. J. Cancer</i> , 118:2639-2643, 2006.
	C3	Bowie <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 147:1306-1310, 1990.
	C4	Curti, "Physical Barriers to Drug Delivery in Tumors", <i>Crit. Rev. Oncol./Hematol.</i> , 14:29-39, 1993.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003082	Serial No. 10/620,850
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Pages 1, 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Goren <i>et al.</i> , "Targeting of Stealth Liposomes in erbB-2 (HER/2) Receptor: In Vitro and In Vivo Studies", <i>Brit. J. Cancer</i> , 74:1749-1756, 1996.
	C6	Gura, "Systems for Identifying New Drugs Are Often Faulty", <i>Science</i> , 278:1041-1042, 1997.
	C7	Güssow and Seemann, "Humanization of Monoclonal Antibodies", <i>Methods in Enzymology</i> , 203:99-121, 1991.
	C8	Herbert <i>et al.</i> , Eds., Dictionary of Immunology, 4th ed. London:Academic Press, 1995.
	C9	Huang <i>et al.</i> , "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice", <i>Cancer Res.</i> , 65(10):4408-4416, 2005.
	C10	Ishida <i>et al.</i> , A Combinatorial Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs", <i>FEBS Letters</i> , 460:129-133, 1999.
	C11	Jain, "Barriers to Drug Delivery in Solid Tumors", <i>Scientific American.</i> , 271(1):58-65, 1994.
	C12	Janeway <i>et al.</i> , "The Interaction of the Antibody Molecule with Specific Antigen", <i>Immunobiology</i> , 5th ed., 7 pages, 2001.
	C13	Lewis <i>et al.</i> , "Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies", <i>Cancer Immunol. Immunother.</i> , 37:255-263, 1993.
	C14	Luster <i>et al.</i> , "Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells," <i>JBC Papers in Press</i> , www.jbc.org/cgi/doi/10.1074/jbc.M605252001 , 2006.
	C15	Maneta-Peyret <i>et al.</i> , "Demonstration of High Specificity Antibodies Against Phosphatidylserine", <i>J. Immunol. Methods</i> , 108:123-127, 1988.
	C16	Mariyama <i>et al.</i> , "Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes", <i>Proc. Natl. Acad. Sci. USA</i> , 87:5744-5748, 1990.
	C17	Mellman, "Where Next for Cancer Immunotherapy?", <i>The Scientist</i> , 20(1):47-56, 2006.
	C18	Ran and Thorpe, "Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy", <i>Int. J. Radiation Oncology Biol. Phys.</i> , 54(5):1479-1484, 2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003082	Serial No. 10/620,850
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Pages 1, 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Ran <i>et al.</i> , "Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice", <i>Clin. Cancer Res.</i> , 11:1551-1562, 2005.
	C20	Ran <i>et al.</i> , "Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels", <i>Cancer Res.</i> , 62:6132-6140, 2002.
	C21	Rote <i>et al.</i> , "Immunologic Detection of Phosphatidylserine Externalization During Thrombin-Induced Platelet Activation", <i>Clinical Immunology and Immunopathology</i> , 66:193-200, 1993.
	C22	Rudikoff, "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci. USA</i> , 79:1979-1983, 1982.
	C23	Schneider-Gadicke and Riethmüller, "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours", <i>Exp. J. Cancer</i> , 31A(7/8):1326-1330, 1995.
	C24	Stancovski <i>et al.</i> , "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth", <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695, 1991.
	C25	Strobel and Cannistra, "β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro", <i>Gynecologic Oncology</i> , 73:362-367, 1999.
	C26	Thorpe <i>et al.</i> , "Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors", <i>Proceeding of the American Association for Cancer Research</i> , 36:488, Abstract #2910, March 1995.
	C27	Umeda <i>et al.</i> , "Effective Production of Monoclonal Antibodies Against Phosphatidylserine: Stereoc-specific Recognition of Phosphatidylserine by Monoclonal Antibody", <i>J. Immunol.</i> , 143:2273-2279, 1989.
	C28	Contractual European Search Report for counterpart PCT Application, PCT/US03/21925, mailed March 31, 2004.
	C29	European Search Report for Counterpart European Application No. 03764600.7, dated Dec. 27, 2004.
	C30	International Search Report for counterpart PCT Application, PCT/US03/21925, mailed Feb. 24, 2005.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT